Compare Heron Therapeutics Inc (HRTX) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs STMicroelectronics NV — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while STMicroelectronics NV trades at $53.7 (market cap $50.29B). The key difference: STMicroelectronics NV is far larger — about 679.2× Heron Therapeutics Inc's market cap, and STMicroelectronics NV pays a 0.64% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and STMicroelectronics NV for 66 Days on average.
| HRTX | STM | |
|---|---|---|
Market Cap | $74.04M | $50.29B |
Volume | 3,668,095 | 9,536,788 |
Sector | Health | Technology |
52-Week High | $1.49 | $79.91 |
52-Week Low | $0.27 | $21.20 |
Typical Hold Time | 35 Days | 66 Days |
Enterprise Value | $180.78M | $47.81B |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
STM (STMicroelectronics) trades at $52.71, down 10.24% in the last session. The stock shows a bullish technical signal with moving averages supporting an uptrend, though oscillators are neutral. Fundamentally, revenue declined to $11.80B in 2025 with a net income margin of -0.39%, but recent Q2 2026 earnings beat expectations. Analyst sentiment is positive with a consensus price target of $77.31. Recent news highlights recovery in automotive and industrial demand, with AI data-center revenue projected to exceed $2B by 2027.
The outlook for STM hinges on execution in AI and automotive segments, offering growth potential, but risks include margin pressures from fab transitions and competitive threats. Wall Street's buy rating majority (51.72%) reflects optimism, though investors should monitor earnings consistency and debt levels, with the stock trading below consensus target indicating potential upside if recovery sustains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
